Metraipolis › archive › dc_5407bc3ea67c

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab — Europe PMC PMID:41199847

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41199847
DOI
10.3389/fonc.2025.1681420
License (as archived)
solo-consultazione
Archived
2026-11-09T04:04:31.975Z
SHA-256 of the archived text
8e57905384a5a2cefe95c88b64143ea2e9ac3e10e3530916f370f2fffa9bbe92
Stable URL of this page
https://metraipolis.com/documento/dc_5407bc3ea67c

How to cite

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab — Europe PMC PMID:41199847 — Europe PMC (en), https://europepmc.org/article/MED/41199847 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5407bc3ea67c (Metraipolis archive dc_5407bc3ea67c, sha256 8e57905384a5a2cefe95c88b64143ea2e9ac3e10e3530916f370f2fffa9bbe92)
BibTeX
@misc{dc5407bc3ea67c,
  title = {Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab — Europe PMC PMID:41199847},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41199847},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5407bc3ea67c; sha256 8e57905384a5a2cefe95c88b64143ea2e9ac3e10e3530916f370f2fffa9bbe92},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41199847. Agents can read the archived copy with the MCP tool read_document.